bicalutamide has been researched along with Sensitivity and Specificity in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawahara, T; Miyoshi, Y; Noguchi, K; Otani, M; Teranishi, J; Uemura, H; Yamanaka, S; Yao, M; Yokomizo, Y | 1 |
| Catalán, R; Morote, J; Planas, J; Raventós, CX; Reventós, J; Salvador, C | 1 |
| Adapa, VS; Kura, RR; Nanduri, VV | 1 |
| Bennett, HL; Fleming, JT; Leung, HY; Mandal, R; O'Prey, J; Robson, CN; Ryan, KM; Stockley, J | 1 |
| Clarke, L; Gandhi, S; Hirsch, M; Penson, DF; Ramsey, S; Veenstra, D | 1 |
5 other study(ies) available for bicalutamide and Sensitivity and Specificity
| Article | Year |
|---|---|
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Flutamide; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tosyl Compounds; Treatment Outcome | 2016 |
Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Gonadotropin-Releasing Hormone; Humans; Luminescent Measurements; Male; Middle Aged; Nitriles; Prospective Studies; Prostatic Neoplasms; Sensitivity and Specificity; Testosterone; Tosyl Compounds | 2009 |
Development and validation of stability-indicating HPLC and UPLC methods for the determination of bicalutamide.
Topics: Anilides; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Least-Squares Analysis; Nitriles; Reproducibility of Results; Sensitivity and Specificity; Tosyl Compounds | 2012 |
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Flow Cytometry; Humans; Immunohistochemistry; Male; Microscopy, Confocal; Nitriles; Prostatic Neoplasms; RNA, Small Interfering; Sensitivity and Specificity; Taxoids; Tosyl Compounds | 2013 |
The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Topics: Androgen Antagonists; Anilides; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostatic Neoplasms; Quality of Life; Sensitivity and Specificity; Tosyl Compounds | 2005 |